- Home
- SPRO vs VRCA Comparison
SPRO vs VRCA Comparison
Compare SPRO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- VRCA
- Stock Information
- Founded
- SPRO 2013
- VRCA 2013
- Country
- SPRO United States
- VRCA United States
- Employees
- SPRO N/A
- VRCA N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- VRCA Health Care
- Exchange
- SPRO Nasdaq
- VRCA Nasdaq
- Market Cap
- SPRO 63.0M
- VRCA 59.8M
- IPO Year
- SPRO 2017
- VRCA 2018
- Fundamental
- Price
- SPRO $0.97
- VRCA $0.66
- Analyst Decision
- SPRO Buy
- VRCA Hold
- Analyst Count
- SPRO 4
- VRCA 5
- Target Price
- SPRO $5.00
- VRCA $6.00
- AVG Volume (30 Days)
- SPRO 247.7K
- VRCA 689.6K
- Earning Date
- SPRO 11-14-2024
- VRCA 02-27-2025
- Dividend Yield
- SPRO N/A
- VRCA N/A
- EPS Growth
- SPRO N/A
- VRCA N/A
- EPS
- SPRO 0.06
- VRCA N/A
- Revenue
- SPRO $106,455,000.00
- VRCA $9,210,000.00
- Revenue This Year
- SPRO N/A
- VRCA $64.32
- Revenue Next Year
- SPRO N/A
- VRCA $83.90
- P/E Ratio
- SPRO $15.29
- VRCA N/A
- Revenue Growth
- SPRO 37.01
- VRCA 187.45
- 52 Week Low
- SPRO $0.92
- VRCA $0.61
- 52 Week High
- SPRO $1.89
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- SPRO 39.40
- VRCA 37.84
- Support Level
- SPRO $0.92
- VRCA $0.62
- Resistance Level
- SPRO $1.13
- VRCA $0.76
- Average True Range (ATR)
- SPRO 0.06
- VRCA 0.07
- MACD
- SPRO 0.00
- VRCA 0.01
- Stochastic Oscillator
- SPRO 26.16
- VRCA 25.50
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.